Samsung Bioepis Announces RENFLEXIS™ (infliximab-abda) Now Available in the United States
Samsung Bioepis Co., Ltd. today announced the launch of RENFLEXIS ™ (infliximab-abda), a biosimilar referencing Remicade® (infliximab), in the United States (US). RENFLEXIS ™ was developed by Samsung Bioepis, and is being commercialized in the US by Merck, which is known as MSD outside of the US and Canada. RENFLEXIS™ was approved by the US Food and Drug Administration (FDA) in April 2017.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170724005616/en/
Christopher Hansung Ko, President & CEO of Samsung Bioepis. (Photo: Business Wire)
“Since we were established five years ago, we have strived to bring high-quality treatment options at a lower cost to US patients. RENFLEXIS is our first step in meeting this important commitment,” said Christopher Hansung Ko, President & CEO of Samsung Bioepis. “We firmly believe biosimilars will play an instrumental role in making healthcare more accessible to patients across the US, and we will continue our relentless drive to advance one of the industry’s strongest pipelines.”
RENFLEXIS™ will be introduced in the US at a wholesale acquisition cost of USD 753.39, a 35 percent discount to the current wholesale acquisition cost of Remicade®. Wholesale acquisition costs do not include discounts that may be paid on the products.
About RENFLEXIS™ (infliximab-abda) for Injection, 100 mg
RENFLEXIS™ is a tumor necrosis factor (TNF) blocker approved in the U.S. for the following indications.
Crohn’s Disease – RENFLEXIS™ is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy. RENFLEXIS™ is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn’s disease.
Pediatric Crohn’s Disease – RENFLEXIS™ is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy.
Ulcerative Colitis – RENFLEXIS™ is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.
Rheumatoid Arthritis – RENFLEXIS™, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis.
Ankylosing Spondylitis – RENFLEXIS™ is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.
Psoriatic Arthritis – RENFLEXIS™ (infliximab-abda) is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in patients with psoriatic arthritis.
Plaque Psoriasis – RENFLEXIS™ is indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. RENFLEXIS™ should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.
Selected Safety Information about RENFLEXIS™ (infliximab-abda)
Patients treated with infliximab products are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue RENFLEXIS™ if a patient develops a serious infection or sepsis.
Reported infections include:
- Active tuberculosis (TB), including reactivation of latent TB. Patients frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before RENFLEXIS™ use and during therapy. 1, 2 Treatment for latent infection should be initiated prior to RENFLEXIS™ use.
- Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis and pneumocystosis. Patients may present with disseminated, rather than localized, disease. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.
- Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.
The risks and benefits of treatment with RENFLEXIS™ should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Closely monitor patients for the development of signs and symptoms of infection during and after treatment with RENFLEXIS™, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy, who are on treatment for latent TB, or who were previously treated for TB infection.
Risk of infection may be higher in patients greater than 65 years of age, pediatric patients, patients with co-morbid conditions and/or patients taking concomitant immunosuppressant therapy. In clinical trials, other serious infections observed in patients treated with infliximab products included pneumonia, cellulitis, abscess, and skin ulceration.
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including infliximab products. Approximately half of these cases were lymphomas, including Hodgkin's and non-Hodgkin's lymphoma. The other cases represented a variety of malignancies, including rare malignancies that are usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months after the first dose of therapy. Most of the patients were receiving concomitant immunosuppressants.
Postmarketing cases of hepatosplenic T-cell lymphoma, a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including infliximab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported cases have occurred in patients with Crohn’s disease or ulcerative colitis and most were in adolescent and young adult males. Almost all of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF-blocker at or prior to diagnosis. Carefully assess the risks and benefits of treatment with RENFLEXIS™ (infliximab-abda), especially in these patient types.
In clinical trials of all TNF inhibitors, more cases of lymphoma were observed compared with controls and the expected rate in the general population. However, patients with Crohn’s disease, rheumatoid arthritis, or plaque psoriasis may be at higher risk for developing lymphoma. In clinical trials of some TNF inhibitors, including infliximab products, more cases of other malignancies were observed compared with controls. The rate of these malignancies among patients treated with infliximab products was similar to that expected in the general population, whereas the rate in control patients was lower than expected. Cases of acute and chronic leukemia have been reported with postmarketing TNF-blocker use. As the potential role of TNF inhibitors in the development of malignancies is not known, caution should be exercised when considering treatment of patients with a current or a past history of malignancy or other risk factors such as chronic obstructive pulmonary disease (COPD).
Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF-blocker therapy, including infliximab products. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.
RENFLEXIS™ (infliximab-abda) is contraindicated in patients with moderate to severe (NYHA Class III/IV) congestive heart failure (CHF) at doses greater than 5 mg/kg. Higher mortality rates at the 10 mg/kg dose and higher rates of cardiovascular events at the 5 mg/kg dose have been observed in these patients. RENFLEXIS™ should be used with caution and only after consideration of other treatment options. Patients should be monitored closely. Discontinue RENFLEXIS™ if new or worsening CHF symptoms appear. RENFLEXIS™ should not be (re)administered to patients who have experienced a severe hypersensitivity reaction or to patients with hypersensitivity to murine proteins or other components of the product.
HEPATITIS B REACTIVATION
TNF inhibitors, including infliximab products, have been associated with reactivation of hepatitis B virus (HBV) in patients who are chronic carriers. Some cases were fatal. Patients should be tested for HBV infection before initiating RENFLEXIS™. For patients who test positive, consult a physician with expertise in the treatment of hepatitis B. Exercise caution when prescribing RENFLEXIS™ for patients identified as carriers of HBV and monitor closely for active HBV infection during and following termination of therapy with RENFLEXIS™. Discontinue RENFLEXIS™ in patients who develop HBV reactivation and initiate antiviral therapy with appropriate supportive treatment. Exercise caution when considering resumption of RENFLEXIS™ and monitor patients closely.
Severe hepatic reactions, including acute liver failure, jaundice, hepatitis, and cholestasis have been reported rarely in patients receiving infliximab products postmarketing. Some cases were fatal or required liver transplant. Aminotransferase elevations were not noted prior to discovery of liver injury in many cases. Patients with symptoms or signs of liver dysfunction should be evaluated for evidence of liver injury. If jaundice and/or marked liver enzyme elevations (e.g., ≥5 times the upper limit of normal) develop, RENFLEXIS™ (infliximab-abda) should be discontinued, and a thorough investigation of the abnormality should be undertaken.
Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia (some fatal) have been reported in patients using infliximab products. The causal relationship to infliximab therapy remains unclear. Exercise caution in patients who have ongoing or a history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs and symptoms of blood dyscrasias or infection. Consider discontinuation of RENFLEXIS™ in patients who develop significant hematologic abnormalities.
Infliximab products have been associated with hypersensitivity reactions that differ in their time of onset. Acute urticaria, dyspnea, and hypotension have occurred in association with infusions of infliximab products. Serious infusion reactions including anaphylaxis were infrequent. Medications for the treatment of hypersensitivity reactions should be available.
TNF inhibitors, including infliximab products, have been associated in rare cases with CNS manifestation of systemic vasculitis, seizure, and new onset or exacerbation of CNS demyelinating disorders, including multiple sclerosis and optic neuritis, and peripheral demyelinating disorders, including Guillain-Barré syndrome. Exercise caution when considering RENFLEXIS™ in patients with these disorders and consider discontinuation if these disorders develop.
Treatment with infliximab products may result in the formation of autoantibodies and, rarely, in development of a lupus-like syndrome. Discontinue treatment if symptoms of a lupus-like syndrome develop.
In clinical trials with infliximab products, the most common adverse reactions occurring in >10% of patients treated with infliximab products included, infections (e.g., upper respiratory, sinusitis, and pharyngitis), infusion-related reactions, headache, and abdominal pain.
USE WITH OTHER DRUGS
Concomitant use of RENFLEXIS™ (infliximab-abda) with anakinra, abatacept, tocilizumab or other biologics used to treat the same conditions as RENFLEXIS™ is not recommended because of the possibility of an increased risk of infection. Care should be taken when switching from one biologic to another, since overlapping biological activity may further increase the risk of infection.
LIVE VACCINES/THERAPEUTIC INFECTIOUS AGENTS
Live vaccines or therapeutic infectious agents should not be given with RENFLEXIS™ due to the possibility of clinical infections, including disseminated infections.
Bring pediatric patients up to date with all vaccinations prior to initiating RENFLEXIS™. At least a 6-month waiting period following birth is recommended before the administration of any live vaccine to infants exposed in utero to infliximab products.
1. American Thoracic Society, Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161:S221-S247.
2. See latest Centers for Disease Control guidelines and recommendations for tuberculosis testing in immunocompromised patients.
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that includes six first-wave candidates that cover the therapeutic areas of immunology, oncology and diabetes. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com.
Please see Prescribing Information for RENFLEXIS (infliximab-abda), including the Boxed Warning about serious infections and malignancies, at http://www.merck.com/product/usa/pi_circulars/r/renflexis/renflexis_pi.pdf and Medication Guide for RENFLEXIS at www.merck.com/product/usa/pi_circulars/r/renflexis/renflexis_mg.pdf .
i Remicade ® is a registered trademark of Janssen Biotech Inc.
Samsung Bioepis Co., Ltd.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Ingersoll Rand Announces Acquisition of ICS Group Holdings Limited, a Leading European Temperature Control and HVAC Solutions Provider22.1.2018 14:30 | Tiedote
Ingersoll-Rand plc (NYSE:IR), a world leader in creating comfortable, sustainable and efficient environments, today announced the acquisition of United Kingdom-based ICS Group Holdings Limited (ICS Cool Energy). ICS Cool Energy will be part of the company’s Commercial Heating, Ventilation and Air Conditioning (HVAC) business. ICS Cool Energy is a privately owned temperature control and HVAC solutions and services company that specializes in temporary rental of energy efficient chillers for commercial and industrial buildings across Europe. It also sells, permanently installs and services high performance temperature control systems for all types of industrial processes. “ICS Cool Energy is a leader in the high margin rental services business with a reputation for strong customer service, helping building owners enhance productivity and reduce environmental impact,” said Dave Regnery, executive vice president of Ingersoll Rand. “This acquisition is a strong fit with our Trane business,
The Geneva Association: Insurance Industry Taking Action in Addressing Climate Change, Although External Hurdles Remain22.1.2018 13:00 | Tiedote
The insurance industry is contributing significantly to building socio-economic resilience to climate change and supporting the transition to a low-carbon economy in their role as risk management experts and investors, although a number of challenges are hindering the industry’s efforts to scale up its contribution, according to a new research report from The Geneva Association, the leading international think tank of the insurance industry. The report ‘Climate Change and the Insurance Industry: Taking Action as Risk Managers and Investors’ is based on interviews with 62 C-level executives of globally active insurance and reinsurance companies, and offers insights into the role of the insurance industry in addressing climate change adaptation and mitigation. Anna Maria D’Hulster, Secretary General of The Geneva Association, commented: “The study has confirmed that climate change is a topic that has made its way up to the boardrooms of the insurance industry, although insurers are neith
Yonnic GmbH Enriches Targeting for Clients with Digital Element’s IP Geolocation Data22.1.2018 12:03 | Tiedote
Leading IP geolocation intelligence company, Digital Element, has today announced that Yonnic GmbH, the industry pioneer of performance marketing solutions, has chosen its NetAcuity technology to boost targeting efficiency for its clients. Yonnic delivers brand relevance for its clients by uncovering and converting consumer intent through its proprietary process Intent-Based Planning tool. Its core application, CloudTDS, provides traffic routing and content delivery based upon a wide range of customisable rules and settings, such as geographical targeting and device specific targeting. By incorporating Digital Element’s NetAcuity data into its solution, Yonnic is able to upgrade its geographical targeting to provide the most accurate solution to its clients. Adding additional IP intelligence datasets such as connection speed, mobile carrier, internet service provider and whether a home or business connection is being used enables Yonnic to further boost its targeting and analytics capa
Vertex Hires Regional Leader to Expand European Presence22.1.2018 11:53 | Tiedote
Vertex, Inc., a leading provider of tax automation solutions, announced Akram El-Rikabi has joined the management team as the regional leader to head European operations. This announcement reflects the company’s growing global presence in the European marketplace and dedication to the international business community. Vertex Vice President of Global Business Development Rebecca Polley states, “Having a proven leadership team and strong regional presence in Europe is critical to engaging with our multinational clients, prospects and partners. In his role, Akram will support Vertex’s growth initiatives by leveraging his expertise in helping customers realize strategic value in their technology investments, especially in the increasingly complex global tax landscape.” El-Rikabi brings 20 years of experience in finance, economics, banking, global partnerships and software management, having worked with global corporations in over 20 countries. Most recently, El-Rikabi was the regional sale
Octapharma: Low inhibitor rate with octanate® in previously untreated patients (PUPs) with severe haemophilia A22.1.2018 11:00 | Tiedote
Octapharma is delighted to announce the publication of final data from a Good Clinical Practice (GCP) trial in PUPs in the internationally renowned medical journal Haemophilia. The study assessed the immunogenicity, efficacy, safety and tolerability of octanate® in PUPs with severe haemophilia A. PUPs with haemophilia A are at greatest risk of inhibitor development. Approximately 35% develop inhibitors, which are associated with detrimental health and economic consequences. In this prospective, multinational study, 51 PUPs with severe haemophilia A received octanate® exclusively as replacement therapy, either prophylactically or for on-demand treatment of bleeds, for a total of 100 exposure days (EDs) or 5 years. Five (9.8%) of the 51 patients developed inhibitors, 4 (7.8%) of which were high titre (≥5 BU/mL) and 1 low titre (<5 BU/mL). All inhibitors developed during on-demand treatment and all 4 high-titre inhibitors developed within the first 20 EDs. All patients who developed inhib
Alkemics to Power productDNA:Hub – an Industry-Led Service to Help Retailers and Suppliers Share Product Data and Images22.1.2018 11:00 | Tiedote
A group of leading UK grocery retailers and suppliers facilitated by GS1 UK, the product data standards organisation, has selected Alkemics to power productDNA:hub, the new service that helps retailers and suppliers to share and manage product data and images. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180122005133/en/ The Alkemics platform that will power productDNA:hub (Photo: Alkemics) Alkemics is a French software platform that facilitates product data sharing between brands and retailers, allowing them to collect and enrich their product data. After a selection phase that included the testing of 25 international solution providers, Alkemics was chosen by the group of leading UK retailers and suppliers to power the collection, standardisation, and sharing of product data among manufacturers, brands, and retailers in the UK. Starting in the spring of 2018, several leading British retailers and brands will use the Alkem
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme